ATXN2 and frontotemporal dementia: To address this gap, our study focused exclusively on individuals diagnosed with ALS/FTD, thereby providing a more homogeneous cohort for evaluating the potential modifying effects of APOE genotype and intermediate polyglutamine repeats in ATXN1 and ATXN2.